In fresh blow, Roche shutters HIV research program

In another big blow to the AIDS research field, pharma giant Roche is dumping its R&D work in the field. The Financial Times reports that disappointing clinical results had persuaded Roche to shutter programs focused on two different ways to attack HIV. Roche has committed its research work to new programs that promise to offer a significant advance on existing therapies.

"While we had initially been hopeful about their potential, we now have concluded that none would provide a true incremental benefit for patients compared to medicines currently on the market," said Jenny Edge-Dallas, global leader for Roche's HIV Franchise.

- read the report from the Financial Times

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."